Articles with "braf" as a keyword



Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.

Sign Up to like & get
recommendations!
Published in 2024 at "JAMA oncology"

DOI: 10.1001/jamaoncol.2024.2133

Abstract: Importance BRAF/MEK inhibitors revolutionized the treatment of BRAF V600E-variant anaplastic thyroid carcinoma (BRAFv-ATC), offering improved outcomes for patients with this previously incurable disease. Observations Anaplastic thyroid carcinoma (ATC) accounts for approximately half of thyroid cancer-related… read more here.

Keywords: consensus; cancer; treatment; braf ... See more keywords

Overexpression of the pro-protein convertase furin predicts prognosis and promotes papillary thyroid carcinoma progression and metastasis through RAF/MEK signaling.

Sign Up to like & get
recommendations!
Published in 2023 at "Molecular oncology"

DOI: 10.1002/1878-0261.13396

Abstract: Furin belongs to the pro-protein convertases (PCs) family and its aberrant expression has been documented in various types of cancers; however, its role in thyroid cancer remains unclear. We investigated the expression of furin in… read more here.

Keywords: thyroid carcinoma; furin; ptc; braf ... See more keywords

Landscape of BRAF transcript variants in human cancer

Sign Up to like & get
recommendations!
Published in 2025 at "Molecular Oncology"

DOI: 10.1002/1878-0261.70043

Abstract: The BRAFV600E mutant kinase is widely studied as a cancer driver and therapeutic target. Here, we investigated how the annotation of the BRAF‐reference (ref) and BRAF‐X1 variants has evolved in public databases and addressed challenges… read more here.

Keywords: cancer; braf; braf 220; braf 204 ... See more keywords

BRAF molecular testing in cytopathology: Implications for diagnosis, prognosis, and targeted therapeutics

Sign Up to like & get
recommendations!
Published in 2019 at "Cancer Cytopathology"

DOI: 10.1002/cncy.22209

Abstract: The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that transduces signals from the cell membrane through the mitogen-activated protein kinase (MAPK) phosphorylation cascade to promote global cellular responses including growth, proliferation, survival,… read more here.

Keywords: molecular testing; braf; cytopathology; braf molecular ... See more keywords

Feasibility and performance of the Idylla™ NRAS/BRAF cartridge mutation assay on thyroid liquid-based fine-needle aspiration.

Sign Up to like & get
recommendations!
Published in 2021 at "Diagnostic cytopathology"

DOI: 10.1002/dc.24897

Abstract: BACKGROUND Thyroid nodules with indeterminate cytology represent up to 30% of cases. Molecular testing is now highly recommended to improve management. This study aimed to evaluate the use of the Idylla™ NRAS/BRAF mutation test, a… read more here.

Keywords: mutation; idylla nras; braf; idylla ... See more keywords

New treatment options in hairy cell leukemia with focus on BRAF inhibitors

Sign Up to like & get
recommendations!
Published in 2019 at "Hematological Oncology"

DOI: 10.1002/hon.2594

Abstract: Hairy cell leukemia (HCL) responds initially very well to chemotherapy with purine analogues. However, up to 50% of patients relapse, often multiple times, and become progressively less sensitive to these myelotoxic and immune‐suppressive drugs. At… read more here.

Keywords: treatment; cell leukemia; hairy cell; braf ... See more keywords
Photo from wikipedia

Age‐dependent performance of BRAF mutation testing in Lynch syndrome diagnostics

Sign Up to like & get
recommendations!
Published in 2020 at "International Journal of Cancer"

DOI: 10.1002/ijc.33273

Abstract: BRAF V600E mutations have been reported as a marker of sporadic microsatellite instability (MSI) colorectal cancer (CRC). Current international diagnostic guidelines recommend BRAF mutation testing in MSI CRC patients to predict low risk of Lynch… read more here.

Keywords: age; braf testing; braf; mutation testing ... See more keywords
Photo from wikipedia

Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo

Sign Up to like & get
recommendations!
Published in 2021 at "Molecular Carcinogenesis"

DOI: 10.1002/mc.23284

Abstract: Mutations in the BRAF gene are highly prevalent in thyroid cancer. However, the response rate of thyroid tumors to BRAF‐directed therapies has been mixed. Increasingly, combination therapies inhibiting the MAPK pathway at multiple nodes have… read more here.

Keywords: braf; inhibition; thyroid cancer; braf erk1 ... See more keywords

FAM129B‐dependent activation of NRF2 promotes an invasive phenotype in BRAF mutant melanoma cells

Sign Up to like & get
recommendations!
Published in 2021 at "Molecular Carcinogenesis"

DOI: 10.1002/mc.23295

Abstract: Incidence of melanoma continues to rise in the United States with ~100,000 new cases diagnosed in 2019. While the 5‐year survival rate of melanoma is 99% when localized, the rate of survival drops to 22.5%… read more here.

Keywords: melanoma; mutant melanoma; braf; melanoma cells ... See more keywords
Photo from wikipedia

The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference

Sign Up to like & get
recommendations!
Published in 2020 at "International Journal of Colorectal Disease"

DOI: 10.1007/s00384-020-03589-9

Abstract: Purpose BRAF mutations represent the main negative prognostic factor for metastatic colorectal cancer and a supposed negative predictive factor of response to standard chemotherapy. We have explored survival difference in right-sided colon cancer (RCC) patients… read more here.

Keywords: braf mutant; right sided; difference; braf ... See more keywords

Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis

Sign Up to like & get
recommendations!
Published in 2017 at "Virchows Archiv"

DOI: 10.1007/s00428-017-2092-4

Abstract: Pulmonary Langerhans cell histiocytosis (PLCH) is a rare, smoking-related histiocytic disorder with variable clinical symptoms. Like in other non-pulmonary Langerhans cell proliferations, PLCH has recently been shown to harbour BRAF V600E mutations in a significant… read more here.

Keywords: langerhans cell; braf v600e; braf; pulmonary langerhans ... See more keywords